Clinical trials: Purpura
Acquired Thrombotic Thrombocytopenic Purpura
Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis
- Trial name
- HERCULES (NCT02553317)
- Testing
- Caplacizumab
- Where
- 101 sites in United States, Australia and 14 more
- Volunteers
- 145 people
- Sponsor
- Ablynx, a Sanofi company
Skin Health, Skin Aging of Face and Hands
The Effect of Nutritional Supplementation on Actinic Purpura: A Pilot Study
Purpura is a macule or papule of blood in the skin. It is mostly seen in mature skin that is often prone to significant bruising.
- Conditions
- Skin Health, Skin Aging of Face and Hands, Healthy, Ecchymosis
- Trial name
- NCT06840574
- Testing
- Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, Low Dose Vitamin C, High Dose Vitamin C
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Standard Process Inc.
Immune Thrombocytopenic Purpura (ITP)
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic…
- Trial name
- NCT03866577
- Testing
- Biological: M254, Intravenous immunoglobulin (IVIg)
- Where
- 28 sites in United States, Belgium and 5 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Purpura, Thrombocytopaenic, Idiopathic
A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
Chronic immune thrombocytopenia (ITP) is a longterm disease in which the blood does not clot normally. This is due to a low number of blood cell fragments called platelets.
- Trial name
- NCT01440361
- Testing
- Belimumab
- Sponsor
- GlaxoSmithKline
Immune Thrombocytopenia (ITP)
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP.
- Trial name
- NCT07095127
- Testing
- NVG-2089
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nuvig Therapeutics, Inc.
Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP)
Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions
This is an open-label, randomized, crossover Phase 1 study to evaluate the bioequivalence, pharmacokinetics, and safety of two oral SKI-O-703 drugs (test and reference) in healthy adults under fed conditions.
- Conditions
- Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP), Rheumatoid Arthritis (RA)
- Trial name
- NCT07675226
- Testing
- SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Oscotec Inc.
Thrombocytopaenia
Meta-analysis - Eltrombopag
The purpose of the meta-analysis was to explore the efficacy of eltrombopag versus placebo (standard of care)
- Trial name
- NCT01235988
- Testing
- Eltrombopag
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
OM336 in Autoimmune Cytopenias
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
- Conditions
- AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
- Trial name
- NCT07083960
- Testing
- OM336
- Where
- 7 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Lakefront Biotherapeutics West LLC
Purpura, Thrombocytopaenic, Idiopathic
EXTEND (Eltrombopag Extended Dosing Study)
An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag…
- Trial name
- EXTEND (NCT00351468)
- Testing
- eltrombopag olamine (SB-497115-GR)
- Where
- 110 sites in United States, Australia and 29 more
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Thrombotic Thrombocytopenic Purpura
Octaplas Adult TTP Trial
To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in…
- Trial name
- NCT01938404
- Testing
- Octaplas, Standard Plasma
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Octapharma
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06371417
- Testing
- RAY121
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Thrombocytopenic Purpura
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to assess the safety and tolerability of AMG 531 (romiplostim), a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in adults with immune thrombocytopenic purpura.
- Trial name
- NCT00117143
- Testing
- Romiplostim
- Volunteers
- 16 people
- Sponsor
- Amgen
Primary Immune Thrombocytopenia
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia…
- Trial name
- myOpportunITy2 (NCT04224688)
- Testing
- Rozanolixizumab
- Where
- 29 sites in United States, Bulgaria and 9 more
- Volunteers
- 30 people
- Sponsor
- UCB Biopharma SRL
Immune Thrombocytopenia (ITP)
The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
This is a randomized, double blinded, placebo-controlled phase Ib clinical trial in adult patients with immune thrombocytopenia. Cross-over treatment will be allowed during the study.
- Trial name
- NCT03951623
- Testing
- HMPL-523
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Hutchison Medipharma Limited
Immune Thrombocytopenia (ITP)
A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206.
- Trial name
- NCT06853444
- Testing
- ESG206
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
Purpura, Thrombocytopaenic, Idiopathic
Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment
The main purpose of this study is to compare how one 50 mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe kidney problems.
- Trial name
- NCT00442871
- Testing
- eltrombopag
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immune Thrombocytopenia
A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag
This study aims to describe the treatment patterns and clinical outcomes of treatment with eltrombopag in primary immune thrombocytopenia (ITP) patients treated with prior corticosteroid therapy.
- Trial name
- NCT07587723
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Idiopathic Thrombocytopenic Purpura
Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive Hetrombopag.
- Trial name
- NCT02614846
- Testing
- Hetrombopag Olamine
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Immune Thrombocytopenia, ITP
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
This is a multi-center, observational, Phase 4 study in patients with Immune Thrombocytopenia (ITP) designed to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge…
- Trial name
- ADOPT (NCT04943042)
- Testing
- Avatrombopag
- Where
- 55 sites in Croatia, Czechia and 7 more
- Volunteers
- 199 people
- Sponsor
- Swedish Orphan Biovitrum
Immune Thrombocytopenia
Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
The purpose of this study is to investigate the efficacy, safety of Hetrombopag in children with previously treated chronic immune thrombocytopenia who are between 6 and 17 years of age. This is a 2 part study.
- Trial name
- NCT04737850
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.